Volume 68, Pages S24-S28 (July 2005)

Slides:

Advertisements

Similar presentations

Hyperparathyroidism in Chronic Kidney Disease 醫五李政霆.

Advertisements

Volume 68, Pages S24-S28 (July 2005)

Volume 69, Issue 1, Pages (January 2006)

Volume 79, Pages S3-S8 (April 2011)

RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone Eduardo A. Slatopolsky, Steven K.

E. Cavalier, P. Delanaye, A. Carlisi, J. -M. Krzesinski, J. -P

Volume 67, Pages S1-S7 (June 2005)

Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation Jordi Bover,

Chapter 3.1: Diagnosis of CKD–MBD: biochemical abnormalities

Frederik Persson, Peter Rossing Kidney International Supplements

Anemia management in chronic kidney disease

Mitchell H. Rosner, W. Kline Bolton Kidney International

Volume 79, Issue 9, Pages (May 2011)

Volume 83, Issue 3, Pages (March 2013)

FGF23 or PTH: which comes first in CKD ?

Chapter 3.1: Diagnosis of CKD–MBD: biochemical abnormalities

RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone Eduardo A. Slatopolsky, Steven K.

Volume 67, Issue 2, Pages (February 2005)

FGF23–parathyroid interaction: implications in chronic kidney disease

Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets David M. Spiegel, Kate Brady Kidney.

Reassessment of the care of the patient with chronic kidney disease

Volume 79, Pages S24-S27 (April 2011)

Volume 79, Pages S3-S8 (April 2011)

M. Fukagawa, S. Nakanishi, J.J. Kazama Kidney International

Haiyan Wang, Luxia Zhang, Jicheng Lv Kidney International

Chapter 3: Management of progression and complications of CKD

Need for better diabetes treatment for improved renal outcome

National Kidney Foundation American Journal of Kidney Diseases

Volume 76, Pages S50-S99 (August 2009)

Volume 71, Issue 1, Pages (January 2007)

Volume 70, Pages S21-S25 (December 2006)

Volume 70, Pages S12-S15 (July 2006)

Volume 60, Issue 5, Pages (November 2001)

Volume 66, Pages S13-S17 (September 2004)

Tally Naveh-Many, Justin Silver Kidney International

Circulating PTH molecular forms: What we know and what we don't

D. Batlle, P. Ramadugu, M.J. Soler Kidney International

A new era in phosphate binder therapy: What are the options?

Volume 70, Issue 11, Pages (December 2006)

Volume 79, Pages S20-S23 (April 2011)

Use of vitamin D in chronic kidney disease patients

Volume 87, Issue 2, Pages (February 2015)

Paricalcitol therapy for secondary hyperparathyroidism in patients on maintenance hemodialysis previously treated with calcitriol: A single-center crossover.

Volume 67, Pages S33-S36 (June 2005)

Volume 79, Issue 1, Pages (January 2011)

Volume 67, Issue 2, Pages (February 2005)

Correction to "Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate.

The calcium–phosphorus in guidelines for CKD-MBD

Vitamin D receptor: A highly versatile nuclear receptor

Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism

Volume 74, Pages S88-S93 (December 2008)

Volume 56, Pages S31-S37 (December 1999)

Methods for guideline development

Volume 68, Issue 3, Pages (September 2005)

A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease S. Susan Hedayati, Venkata Yalamanchili,

Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease C.P. Kovesdy, S. Ahmadzadeh,

Volume 75, Issue 9, Pages (May 2009)

Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics William G. Goodman, L.D. Quarles

Fibroblast growth factor 23: the making of a hormone

Volume 72, Issue 2, Pages (July 2007)

Pablo A. Ureña Torres, Marc De Broe Kidney International

Volume 55, Pages S3-S16 (June 1999)

Volume 69, Issue 1, Pages (January 2006)

Recent developments in the management of secondary hyperparathyroidism

Increased fetuin-A levels following treatment with a vitamin D analog

In chronic kidney disease staging the use of the chronicity criterion affects prognosis and the rate of progression B.O. Eriksen, O.C. Ingebretsen Kidney.

Volume 74, Issue 10, Pages (November 2008)

Volume 61, Issue 4, Pages (April 2002)

What Should a Guideline Panel Do When Evidence Is Inconclusive

Volume 64, Pages S131-S136 (November 2003)

Presentation transcript:

Volume 68, Pages S24-S28 (July 2005) Cinacalcet HCl: A novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease L. Darryl Quarles Kidney International Volume 68, Pages S24-S28 (July 2005) DOI: 10.1016/S0085-2538(15)51229-5 Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 1 Molecular targets regulating parathyroid gland function include, in rank order of importance, CASR, VDR, and a hypothetical phosphate sensing mechanism. Kidney International 2005 68, S24-S28DOI: (10.1016/S0085-2538(15)51229-5) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 2 Changes in serum PTH, calcium, phosphorus, and Ca × P product in placebo- and cinacalcet HCl (AMG073)-treated patients enrolled in a phase II trial. Reprinted with permission from Lippincott Williams & Wilkins. Kidney International 2005 68, S24-S28DOI: (10.1016/S0085-2538(15)51229-5) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 3 Mean (±SEM) plasma parathyroid hormone levels as a function of time in the combined phase III trials comparing placebo with cinacalcet HCl treatment in stage 5 CKD patients. Reprinted with permission from Massachusetts Medical Society. Modified from National Kidney Foundation K/DOQI™, Am J Kidney Dis 43:S1–S201, 2004. Kidney International 2005 68, S24-S28DOI: (10.1016/S0085-2538(15)51229-5) Copyright © 2005 International Society of Nephrology Terms and Conditions